NEO PanTracer Tissue (formerly Neo Comprehensive - Solid Tumor)
Use
The NEO PanTracer Tissue is a broad next-generation sequencing panel designed for the detection of mutations in solid tumor specimens. It identifies single nucleotide variants (SNVs), insertions/deletions (InDels), copy number variants (CNVs), and RNA fusions and splice variants in a comprehensive list of 517 genes. Additionally, it assesses genomic signatures such as microsatellite instability (MSI) and tumor mutational burden (TMB), which can aid in developing targeted therapeutic strategies for cancer treatment.
Special Instructions
A block is preferred for testing with specific requirements: >20% tumor and >5 mm2 of tissue surface area for NGS (~500 tumor cells) and additional 100 neoplastic cells for PD-L1 testing. If submitting unstained slides, the number varies based on the tissue area. Extra slides are needed for H&E and PD-L1 testing. Use cold packs for transport, ensuring they do not directly contact specimens.
Limitations
The assay's performance may vary based on specimen quality, quantity, and handling. Limited detection of low-frequency mutations and absence of certain biomarkers may affect results. Some samples might not provide sufficient quality or quantity of nucleic acids for complete analysis.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
8-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Storage Instructions
Use cold pack for transport, ensuring the pack is not in direct contact with the specimen.